Insilico Medicine Launches AI-Powered Virtual Aging Cell
Hong Kong, August 14, 2026 Insilico Medicine, a clinical-stage drug discovery company powered by generative artificial intelligence (AI), has...
Obesity
Advertisement
Insilico and THPharm Expand AI Drug Development Strategy
Seoul, South Korea, August 12, 2026 THPharm is advancing an artificial intelligence-driven indication expansion strategy in partnership with Insilico...
Biomea Fusion Doses First Patient in Obesity OPAL Study
SAN CARLOS, Calif., August 13, 2026 Biomea Fusion, Inc. announced that the first participant has been dosed in a...
Kalohexis Appoints Jeffrey Sherman to Board of Directors
Northbrook, Illinois, August,11, 2026 Kalohexis, Inc., a clinical-stage biotechnology company developing therapies that target the melanocortin system, has appointed...
Veru Advances PLATEAU Trial with Full Enrollment
Miami, Florida, August 10, 2026 Veru Inc. has announced full enrollment of 239 patients in its Phase 2b PLATEAU...
Advertisements
Vivani Medical Completes Phase 1 SLIM-1 Dosing of NPM-139 Implant
ALAMEDA, Calif., August 6, 2026 Vivani Medical, Inc. announced the successful full enrollment and initial dosing of all 20...
UCB Reports FINTEPLA Study Showing Sustained LGS Benefits
Atlanta, Georgia, August 5, 2026 UCB has announced the publication of a post hoc analysis in Epilepsia Open demonstrating...
Novo Nordisk Wins Dutch Injunction Over Semaglutide Spray
Bagsværd, Denmark, August 5, 2026 Novo Nordisk has secured a significant legal victory after the District Court of The...
Ascletis Launches Global Phase III Trial of Oral GLP-1 ASC30
Hong Kong – August 3, 2026 Ascletis Pharma Inc. has initiated a global Phase III clinical development program for...
Verdiva Bio Starts Phase 1 Trial of Weekly Oral VRB-103
LONDON and SAN FRANCISCO, July 30, 2026 Verdiva Bio announced that the first patient has been dosed in a...
Advertisement
